Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.
Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P, Dolev M, Menascu S, Flechter S, Falb R, Gurevich M. Achiron A, et al. Among authors: falb r. Ther Adv Neurol Disord. 2021 Apr 22;14:17562864211012835. doi: 10.1177/17562864211012835. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34035836 Free PMC article.
Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.
Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P, Dolev M, Menascu S, Flechter S, Falb R, Gurevich M. Achiron A, et al. Among authors: falb r. Ther Adv Neurol Disord. 2021 May 29;14:17562864211020082. doi: 10.1177/17562864211020082. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34104221 Free PMC article. No abstract available.
COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose.
Dreyer-Alster S, Menascu S, Mandel M, Shirbint E, Magalashvili D, Dolev M, Flechter S, Givon U, Guber D, Stern Y, Miron S, Polliack M, Falb R, Sonis P, Gurevich M, Achiron A. Dreyer-Alster S, et al. Among authors: falb r. J Neurol Sci. 2022 Mar 15;434:120155. doi: 10.1016/j.jns.2022.120155. Epub 2022 Jan 21. J Neurol Sci. 2022. PMID: 35091386 Free PMC article.
In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab.
Achiron A, Mandel M, Dreyer-Alster S, Magalashvili D, Menascu S, Warszawer Y, Dolev M, Didikin M, Harari G, Sonis P, Falb R, Gurevich M. Achiron A, et al. Among authors: falb r. Mult Scler Relat Disord. 2023 Apr;72:104616. doi: 10.1016/j.msard.2023.104616. Epub 2023 Mar 12. Mult Scler Relat Disord. 2023. PMID: 36933299 Free PMC article.
Further delineation of the SCAF4-associated neurodevelopmental disorder.
Schmid CM, Gregor A, Ruiz A, Manso Bazús C, Herman I, Ammouri F, Kotzaeridou U, McNiven V, Dupuis L, Steindl K, Begemann A, Rauch A, Suter AA, Isidor B, Mercier S, Nizon M, Cogné B, Deb W, Besnard T, Haack TB, Falb RJ, Müller AJ, Linden T, Haldeman-Englert CR, Ockeloen CW, Mattioli F, Reymond A, Ibrahim N, Naz S, Lacaze E, Bassetti JA, Hoefele J, Brunet T, Riedhammer KM, Elloumi HZ, Person R, Zou F, Kahle JJ, Cremer K, Schmidt A, Delrue MA, Almeida PM, Ramos F, Srivastava S, Quinlan A, Robertson S, Manka E, Kuechler A, Spranger S, Nowaczyk MJM, Elshafie RM, Alsharhan H, Hillman PR, Dunnington LA, Braakman HMH, McKee S, Moresco A, Ignat AD, Newbury-Ecob R, Banneau G, Patat O, Kuerbitz J, Rzucidlo S, Sell SS, Gordon P, Schuhmann S, Reis A, Halleb Y, Stoeva R, Keren B, Al Masseri Z, Tümer Z, Hammer-Hansen S, Krüger Sølyst S, Steigerwald CG, Abreu NJ, Faust H, Müller-Nedebock A, Tran Mau-Them F, Sticht H, Zweier C. Schmid CM, et al. Among authors: falb rj. Eur J Hum Genet. 2024 Dec 12. doi: 10.1038/s41431-024-01760-2. Online ahead of print. Eur J Hum Genet. 2024. PMID: 39668183
36 results